Medicine approval and sport status are independent. The current World Anti-Doping Agency list can name a substance, cover a broader class, distinguish timing, or place an item in a separate Monitoring Program.
This 2026 snapshot summarizes the central WADA and sport brief. Athletes and support teams must verify the current list, exact identity, class wording, and applicable rules rather than relying on an older article or a market name.
The architecture of the Prohibited List
| Category | What it covers in the 2026 source | Existing examples | Timing or status caveat |
|---|---|---|---|
| WADA Prohibited List class S0 (non-approved substances): pharmacological substances not addressed elsewhere in the list and with no current approval by any governmental regulatory health authority for human therapeutic use. 定义来源: WADA and sport regulation brief · 术语表 | Pharmacological substances outside another section that lack current approval by any governmental regulatory health authority for human therapeutic use | BPC-157 is explicitly listed | An unlisted substance is not automatically S0; both conditions require checking |
| WADA Prohibited List class S2 (peptide hormones, growth factors, related substances and mimetics): prohibited at all times, with subsections of materially different scope. 定义来源: WADA and sport regulation brief · 术语表 | Peptide hormones, growth factors, related substances, mimetics, and defined subclasses | AOD-9604, CJC-1295, ipamorelin, and TB-500 | The 2026 source marks S2 as prohibited at all times; subsection and identity still matter |
| S4 | Hormone and metabolic modulators, including named and functionally described classes | MOTS-c, insulins, and myostatin-related examples | The 2026 source marks these subclasses as prohibited at all times |
| Monitoring Program | Substances or markers tracked to identify patterns of use | Semaglutide and tirzepatide markers in the 2026 program | Monitored does not mean prohibited |
S0 — non-approved substances
The 2026 source explicitly lists BPC-157. S0 also has a two-part scope: the substance must fall outside another section and lack current approval by any governmental regulatory health authority for human therapeutic use.
Checking only one or two regulator databases cannot prove worldwide absence of approval for an unnamed substance. That is why the central brief avoids turning “not found here” into an automatic global S0 conclusion.
S2 — peptide hormones and growth factors
S2 contains materially different subclasses. The 2026 source includes growth-hormone fragments such as AOD-9604; growth-hormone-releasing factors and secretagogues such as CJC-1295 and ipamorelin; and growth factors or modulators including thymosin-beta-4 derivatives such as TB-500.
Class wording matters because not every covered substance is individually named. Identity matters because fragments, analogues, agonists, antagonists, derivatives, and ambiguous market names are not interchangeable.
S4 — hormone and metabolic modulators
The 2026 source includes myostatin-related classes, names MOTS-c as an AMPK-activator example, and covers insulins and insulin mimetics in a separate metabolic-modulator subsection.
A therapeutic-use exemption is an individual authorization process; it does not change the prohibited classification of a substance.
- S0: non-approved: BPC-157
- S2: peptide hormones /: growth factors: AOD-9604 · CJC-1295 · TB-500
- S4: metabolic: modulators: MOTS-c · insulins
- MONITORING: tracked ≠: prohibited: semaglutide · tirzepatide
The Monitoring Program
The 2026 Monitoring Program includes markers of semaglutide and tirzepatide, plus a qualified GnRH-analogue category. Monitoring tracks patterns of use; it is not the Prohibited List.
That separation is a useful reminder that authorized medicine, prohibited substance, monitored item, and unlisted item are different statuses.
Not listed does not settle every case
A substance is not prohibited merely because it is a peptide. But absence of an exact name is not always decisive because category definitions can cover classes, analogues, fragments, derivatives, mimetics, metabolites, or biological effects.
Exact ingredient and current wording must be checked. A market blend name does not supply that identity analysis.
How the atlas records sport status
Each monograph keeps The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. 定义来源: WADA and sport regulation brief · 术语表 status separate from medicine authorization, evidence grade, and entry type. The record includes the applicable category, cited current source, and verification date.
The 2026 category map is a dated snapshot, not a permanent ruling. Recheck the current WADA list and Monitoring Program whenever status matters.